Cardiology

Cardiovascular events and death increased by 20% in people with 4 or more depressive symptoms compared to individuals without depressive symptoms.

Twenty two nonprofit organizations have been awarded COVID-19 Rapid Response Grants as part of the American Heart Association’s Voices for Healthy Kids initiative.The grants range from $20,000 to $50,000 and will support work focused on improving access to healthy food, increasing access to health care and addressing income needs during and beyond the pandemic.

Results of the VERTIS-CV trial indicate ertugliflozin could reduce heart failure hospitalizations but did not demonstrate the ability to reduce MACE compared to placebo.

Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.

The prevention of type 2 diabetes is possible and has important clinical benefits.

Sirimon Reutrakul, MD, discusses what providers should do based on the findings of a new study presented at ADA 2020.

Results of a new study are diving deeper into potential mediators of the effects of canagliflozin on heart failure and CV death seen in CREDENCE.

A prespecified exploratory analysis suggests the SGLT2 inhibitor reduced the rate of new-onset diabetes by nearly a third.

Chief Medical Officer of Applied Therapeutics discusses a study presented at ADA 2020 examining use of an aldose reductase inhibitor for diabetic complications.

Silvio Inzucchi, MD, discusses an EMPA-REG OUTCOME analysis assessing the impact of empagliflozin in patients who experience an initial dip in eGFR.

Deepak Bhatt, MD, MPH, discusses the results of the latest REDUCE-IT analysis, titled REDUCE-IT DIABETES, presented at ADA 2020.

Kieran Docherty, MBChB, discusses the results of a DAPA-HF analysis he presented at ADA 2020.

Discussing the effect of canagliflozin in patients with diabetes and chronic kidney disease with Meg Jardine, MBBS, PhD.

Lower treatment odds for women were also observed in a set of 7 studies that had data on the subgroup of patients eligible for IV rtPA treatment.

A look at how the rare pulmonary disease field of research has been limited.

The outcomes of clinical trials are often affected by the diversity of the patient population studied.  Things like race and gender can make a real difference in the way drugs work– and yet women, minorities and older adults continue to be underrepresented in pivotal trials for new medications .  Two recent studies demonstrate that fact over the last several decades.  And although the proportion of these populations enrolled in clinical trials has increased, it is still well out of step with the number of patients affected by the diseases in question. Sr. Editor Gretchen Cuda Kroen spoke with Dr. Erin Michos,  co-author on those studies about the origins of the disparity, and what what we can do about it.

An NIH-funded analysis of the Jackson Heart Study is diving deeper into the impact of smoking on African Americans.

A new study from the University of Arizona is shedding light on the psychological impact of Tai Chi in patients with cardiovascular disease.

Analysis of the Framingham Heart Study indicates the rate of ICH in older patients has been on the rise and suggests anticoagulant use could have contributed to this increase.

Greg Cosgrove, MD, explains how the respiratory condition can be overlooked by patients and clinicians.

A new analysis examines impact of treatment adherence in more than 1.2 million patients.

A new observational analysis from the University of Mississippi Medical Center is disputing the notion marijuana use increases stroke risk.

Despite normally being associated with end of life care, new research suggest palliative care could benefit heart failure patients.

The expanded indication is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy in those with a high risk, but no history of heart attack or stroke.